Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deleobuvir monotherapy in HCV GT1
NCT02176525Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2007
- Primary completion
- Dec 2009
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of deleobuvir in hepatitis C (HCV) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Virologic Response (VR) at Day 5. Started Dec 2007; status: completed.
02
Drugs
deleobuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02176525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02176525.